Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
FULC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.78 - $10.13
Previous CloseN/A
Volume345.04K
Average Volume (3M)449.63K
Market Cap
$166.80M
Enterprise Value$21.19M
Total Cash (Recent Filing)$72.80M
Total Debt (Recent Filing)$30.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 19, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding53,979,305
10 Day Avg. Volume525,335
30 Day Avg. Volume449,629
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.13
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.26
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$5.67Price Target Upside83.50% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Faces Termination of Key Agreement
PremiumCompany Announcements
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains
PremiumCompany Announcements
Fulcrum Therapeutics Reports Strong Financial Position and Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentThe withdrawal of Oxbryta has made it simpler to enroll patients, easing recruitment for FULC's study.
Market OpportunityThe recent global withdrawal of OXBRYTA, a previously approved oral HbF inducer, has created an opportunity for Fulcrum to attract patients who were previously on that therapy.
Regulatory AdvantageIf the 12 mg cohort data is compelling, this could accelerate future clinical trials and regulatory pathways, positioning pociredir as a faster-to-market therapy.
Bears Say
Program UncertaintyAnalyst reiterates an Underperform rating with a price objective of $2, suggesting limited confidence in the stock's potential.
Regulatory ChallengesStudy design includes a brief pause after readout to allow Data Monitoring Committee review, indicating potential delays in the pociredir program's progress.
Study ComplicationsPatients being recruited in the 12mg dose cohort tend to have more disease severity, which could complicate the study outcomes.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.78 and its highest was $10.13 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $166.80M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 51 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Feb 25, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.282 by -$0.028.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 53,979,305 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.282. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
---
Fulcrum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.67 (83.50% Upside)
$5.67 (83.50% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.33%
12-Months-Change
Fundamentals
Return on Equity
-4.07%
Trailing 12-Months
Asset Growth
1.17%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
---
FULC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights positive financial management with a strengthened cash position and reduced net loss, alongside promising progress in the sickle cell disease program. However, the lack of collaboration revenue in Q4 and restructuring costs present challenges. The sentiment is balanced with meaningful progress and ongoing challenges.Read More>---
FULC Stock 12 Month Forecast
Average Price Target
$5.67
▲(83.50% Upside)
Technical Analysis
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering FULC
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
-10.83%
reiterated a sell rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -10.83% per trade.
---